Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07170917 · ClinicalTrials.gov registry record · Phase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT07170917: Recruiting Phase 2 study of Hidradenitis Suppurativa, sponsored by Sanofi.
NCT07170917 is a Phase 2 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Sanofi. The registered enrollment target is 208 participants, below the 594-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07170917, a Phase 2 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 60 weeks for participants not transitioning into the long-term extension (LTE) study and will be up to approximately 52 weeks for participants transitioning into the LTE study. The randomized treatment duration will be up to approximately 48 weeks.
Primary Outcome
Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) is defined as ≥75% reduction from Baseline in the total abscess and inflammatory nodule \[AN\] count, with no increase from Baseline in abscess or draining tunnel count.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brivekimig
Study Locations (20)
Reg Metropolitana de Santiago
- Investigational Site Number: 1520003 - Santiago
- Investigational Site Number: 1520002 - Santiago
- Investigational Site Number: 1520001 - Santiago
- Investigational Site Number: 1520005 - Santiago
Florida
- FXM Clinical Research - Miami- Site Number : 8400017 - Miami
- FXM Clinical Research Miramar, LLC - Site Number: 8400004 - Miramar
Georgia
- Advanced Medical Research - Atlanta- Site Number : 8400011 - Atlanta
- Georgia Skin & Cancer Clinic- Site Number : 8400009 - Savannah
Ontario
- Lima's Excellence in Allergy and Dermatology Research (LEADER) Inc. - Hamilton
- Investigational Site Number : 1240009 - Toronto
California
- Northridge Clinical Trials - Northridge- Site Number : 8400005 - Northridge
Louisiana
- Louisiana Dermatology Associates- Site Number : 8400006 - Baton Rouge
Rhode Island
- Clinical Partners- Site Number : 8400002 - Johnston
South Carolina
- AMR Clinical South Strand, South Carolina- Site Number : 8400018 - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2028-04-27 |
| Phase | Phase 2 |
What NCT07170917 shows while recruiting
NCT07170917 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 594-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07170917 names 20 study sites across 14 states, led by Reg Metropolitana de Santiago, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07170917 about?
NCT07170917 is a clinical study titled "Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa". This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging ...
What is the current status of trial NCT07170917?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2025-11-06. Estimated completion is 2028-04-27.
What conditions does trial NCT07170917 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT07170917?
The interventions under investigation include: Placebo (DRUG), Brivekimig (DRUG).
Who is sponsoring clinical trial NCT07170917?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07170917 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Louisiana, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07170917's enrollment target sits among peer trials
208 23rd of 52 higher than 30 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI